Journal of Nephrology

, Volume 29, Issue 3, pp 391–400 | Cite as

The effect of dapagliflozin on renal function in patients with type 2 diabetes

  • Donald Elliott Kohan
  • Paola Fioretto
  • Kristina Johnsson
  • Shamik Parikh
  • Agata PtaszynskaEmail author
  • Lisa Ying
Original Article



Dapagliflozin’s antihyperglycemic effects are mediated by inhibition of renal sodium-glucose cotransporter-2; therefore, renal safety of dapagliflozin was assessed.


Twelve double-blind, placebo-controlled, randomized clinical trials were analyzed up to 24 weeks (N = 4545). Six of the 12 studies included long-term data for up to 102 weeks (N = 3036). Patients with type 2 diabetes with normal or mildly impaired renal function [estimated glomerular filtration rate (eGFR) 60 to <90 mL/min/1.73 m2] were treated with dapagliflozin (2.5, 5, or 10 mg/day) or placebo. Renal adverse events (AEs) were assessed.


Mean eGFR showed small transient reductions with dapagliflozin at week 1, but returned to near baseline values by week 24 and remained stable to week 102. Mean eGFR changes were not very different for dapagliflozin 2.5, 5 and 10 mg versus placebo at 102 weeks: −0.74, 2.52 and 1.38 versus 1.31 mL/min/1.73 m2, respectively. Renal AEs were similar in frequency to placebo through 24 weeks (1.4, 1.3, 0.9, and 0.9 %, respectively) and 102 weeks (2.4, 1.8, 1.9 and 1.7 %, respectively). Few were serious (0.2, 0.1, 0 and 0.3 %, respectively, over 102 weeks). The most common renal event was serum creatinine increase. In sub-group analyses in patients ≥65 years of age or those with moderate renal impairment (eGFR 30 to <60 mL/min/1.73 m2), renal AEs occurred more frequently with dapagliflozin than placebo. No events of acute tubular necrosis were reported.


In patients with normal or mildly impaired renal function, dapagliflozin is not associated with increased risk of acute renal toxicity or deterioration of renal function. All trials included in this analysis are registered at NCT00263276, NCT00972244, NCT00528372, NCT00736879, NCT00528879, NCT00855166, NCT00357370, NCT00680745, NCT00683878, NCT00673231, NCT00643851, NCT00859898.


Dapagliflozin Renal Safety SGLT2 



The study team would like to acknowledge the patients for their participation and commitment during the studies. We also thank the investigators and contributors from each study site. The authors thank Dr. Bruce Leslie for his involvement with this analysis, Dr James List for his contribution to the analysis and initial manuscript development, and Jennifer Sugg for her contribution to statistical analysis. Professional medical writing and editorial assistance was provided by Carolyn Carroll, PhD, an employee of Bristol-Myers Squibb at the time of the development of this manuscript and Shelley Narula, MBBS, of inScience Communications, Springer Healthcare.


The conduct and analyses of these trials were supported by Bristol-Myers Squibb and AstraZeneca.

Compliance with ethical standards

Conflict of interest

DEK is a consultant for Bristol-Myers Squibb and AstraZeneca. PF is a consultant for Bristol-Myers Squibb and AstraZeneca, and participant in boards for Boehringer Ingelheim. KJ and SP are employees and shareholders of AstraZeneca. AP and LY are employees and shareholders of Bristol-Myers Squibb.

Ethical approval

The analysis in this article is based on previously conducted studies, and does not involve any new studies of human or animal subjects performed by any of the authors.

Informed consent

Informed consent was obtained from all participants.

Supplementary material

40620_2016_261_MOESM1_ESM.docx (55 kb)
Supplementary material 1 (DOCX 59 kb)


  1. 1.
    Wood IS, Trayhurn P (2003) Glucose transporters (GLUT and SGLT): expanded families of sugar transport proteins. Br J Nutr 891:3–9CrossRefGoogle Scholar
  2. 2.
    Kanai Y, Lee WS, You G, Brown D, Hediger MA (1994) The human kidney low affinity Na+/glucose cotransporter SGLT2. Delineation of the major renal reabsorptive mechanism for D-glucose. J Clin Invest 93:397–404CrossRefPubMedPubMedCentralGoogle Scholar
  3. 3.
    Komoroski B, Vachharajani N, Boulton D et al (2009) Dapagliflozin, a novel SGLT2 inhibitor, induces dose-dependent glucosuria in healthy subjects. Clin Pharmacol Ther 85:520–526CrossRefPubMedGoogle Scholar
  4. 4.
    Meng W, Ellsworth BA, Nirschl AA et al (2008) Discovery of dapagliflozin: a potent, selective renal sodium-dependent glucose cotransporter 2 (SGLT2) inhibitor for the treatment of type 2 diabetes. J Med Chem 51:1145–1149CrossRefPubMedGoogle Scholar
  5. 5.
    Han S, Hagan DL, Taylor JR et al (2008) Dapagliflozin, a selective SGLT2 inhibitor, improves glucose homeostasis in normal and diabetic rats. Diabetes 57:1723–1729CrossRefPubMedGoogle Scholar
  6. 6.
    List JF, Whaley JM (2011) Glucose dynamics and mechanistic implications of SGLT2 inhibitors in animals and humans. Kidney Int Suppl 79:S20–S27CrossRefGoogle Scholar
  7. 7.
    Mather A, Pollock C (2011) Glucose handling by the kidney. Kidney Int Suppl 79:S1–S6CrossRefGoogle Scholar
  8. 8.
    Vallon V, Platt KA, Cunard R et al (2011) SGLT2 mediates glucose reabsorption in the early proximal tubule. J Am Soc Nephrol 22:104–112CrossRefPubMedPubMedCentralGoogle Scholar
  9. 9.
    List JF, Woo V, Morales E, Tang W, Fiedorek FT (2009) Sodium-glucose cotransport inhibition with dapagliflozin in type 2 diabetes. Diabetes Care 32:650–657CrossRefPubMedGoogle Scholar
  10. 10.
    Bailey CJ, Gross JL, Pieters A, Bastien A, List JF (2010) Effect of dapagliflozin in patients with type 2 diabetes who have inadequate glycaemic control with metformin: a randomised, double-blind, placebo-controlled trial. Lancet 375:2223–2233CrossRefPubMedGoogle Scholar
  11. 11.
    Ferrannini E, Ramos SJ, Salsali A, Tang W, List JF (2010) Dapagliflozin monotherapy in type 2 diabetic patients with inadequate glycemic control by diet and exercise: a randomized, double-blind, placebo-controlled, phase 3 trial. Diabetes Care 33:2217–2224CrossRefPubMedPubMedCentralGoogle Scholar
  12. 12.
    Strojek K, Yoon KH, Hruba V, Elze M, Langkilde AM, Parikh S (2011) Effect of dapagliflozin in patients with type 2 diabetes who have inadequate glycaemic control with glimepiride: a randomized, 24-week, double-blind, placebo-controlled trial. Diabetes Obes Metab 13:928–938CrossRefPubMedGoogle Scholar
  13. 13.
    Nauck MA, Del Prato S, Meier JJ et al (2011) Dapagliflozin versus glipizide as add-on therapy in patients with type 2 diabetes who have inadequate glycemic control with metformin: a randomized, 52-week, double-blind, active-controlled noninferiority trial. Diabetes Care 34:2015–2022CrossRefPubMedPubMedCentralGoogle Scholar
  14. 14.
    Rosenstock J, Vico M, Wei L, Salsali A, List JF (2012) Effects of dapagliflozin, an SGLT2 inhibitor, on HbA1c, body weight, and hypoglycemia risk in patients with type 2 diabetes inadequately controlled on pioglitazone monotherapy. Diabetes Care 35:1473–1478CrossRefPubMedPubMedCentralGoogle Scholar
  15. 15.
    Wilding JP, Norwood P, T’Joen C, Bastien A, List JF, Fiedorek FT (2009) A study of dapagliflozin in patients with type 2 diabetes receiving high doses of insulin plus insulin sensitizers: applicability of a novel insulin-independent treatment. Diabetes Care 32:1656–1662CrossRefPubMedPubMedCentralGoogle Scholar
  16. 16.
    Wilding JP, Woo V, Soler NG et al (2012) Long-term efficacy of dapagliflozin in patients with type 2 diabetes mellitus receiving high doses of insulin: a randomized trial. Ann Intern Med 156:405–415CrossRefPubMedGoogle Scholar
  17. 17.
    Sharif A (2011) Current and emerging antiglycaemic pharmacological therapies: the renal perspective. Nephrol (Carlton) 16:468–475CrossRefGoogle Scholar
  18. 18.
    Committee for Medicinal Products for Human Use European Public Assessment Report (EPAR) Canagliflozin European Medicines Agency 2013.
  19. 19.
    Yale JF, Bakris G, Cariou B, Nieto J, David-Neto E, Yue D et al (2014) Efficacy and safety of canagliflozin over 52 weeks in patients with type 2 diabetes mellitus and chronic kidney disease. Diabetes Obes Metab 16:1016–1027CrossRefPubMedGoogle Scholar
  20. 20.
    Barnett AH, Mithal A, Manassie J, Jones R, Rattunde H, Woerle HJ et al (2014) Efficacy and safety of empagliflozin added to existing antidiabetes treatment in patients with type 2 diabetes and chronic kidney disease: a randomised, double-blind, placebo-controlled trial. Lancet Diabetes Endocrinol 2:369–384CrossRefPubMedGoogle Scholar
  21. 21.
    Kaku K, Inoue S, Matsuoka O, Kiyosue A, Azuma H, Hayashi N et al (2013) Efficacy and safety of dapagliflozin as a monotherapy for type 2 diabetes mellitus in Japanese patients with inadequate glycaemic control: a phase II multicentre, randomized, double-blind, placebo-controlled trial. Diabetes Obes Metab 15:432–440CrossRefPubMedGoogle Scholar
  22. 22.
    Bailey CJ, Iqbal N, T’joen C, List JF (2012) Dapagliflozin monotherapy in drug-naïve patients with diabetes: a randomized-controlled trial of low-dose range. Diabetes Obes Metab 14:951–959CrossRefPubMedGoogle Scholar
  23. 23.
    Bolinder J, Ljunggren Ö, Kullberg J, Johansson L, Wilding J, Langkilde AM et al (2012) Effects of dapagliflozin on body weight, total fat mass, and regional adipose tissue distribution in patients with type 2 diabetes mellitus with inadequate glycemic control on metformin. J Clin Endocrinol Metab 97:1020–1031CrossRefPubMedGoogle Scholar
  24. 24.
    Henry RR, Murray AV, Marmolejo MH, Hennicken D, Ptaszynska A, List JF (2012) Dapagliflozin, metformin XR, or both: initial pharmacotherapy for type 2 diabetes, a randomised controlled trial. Int J Clin Prac 66:446–456CrossRefGoogle Scholar
  25. 25.
    National Kidney Foundation (2002) Part 4. Definition and classification of stages of chronic kidney disease. Am J Kidney Dis 39:S46–S75CrossRefGoogle Scholar
  26. 26.
    Vallon V, Richter K, Blantz RC, Thomson S, Osswald H (1999) Glomerular hyperfiltration in experimental diabetes mellitus: potential role of tubular reabsorption. J Am Soc Nephrol 10:2569–2576PubMedGoogle Scholar
  27. 27.
    Thomson SC, Rieg T, Miracle C et al (2012) Acute and chronic effects of SGLT2 blockade on glomerular and tubular function in the early diabetic rat. Am J Physiol Regul Integr Comp Physiol 302:R75–R83CrossRefPubMedGoogle Scholar
  28. 28.
    Stevens LA, Coresh J, Greene T, Levey AS (2006) Assessing kidney function—measured and estimated glomerular filtration rate. N Engl J Med 354:2473–2483CrossRefPubMedGoogle Scholar
  29. 29.
    Kohan DE, Fioretto P, Tang W, List JF (2014) Long-term study of patients with type 2 diabetes and moderate renal impairment shows that dapagliflozin reduces weight and blood pressure but does not improve glycemic control. Kidney Int 85:962–971CrossRefPubMedGoogle Scholar
  30. 30.
    Kohan DE, Fioretto P, List J, et al (2011) Efficacy and safety of dapagliflozin in patients with type 2 diabetes and moderate renal impairment. Presented at the American society of nephrology kidney week 2011 annual meeting; Philadelphia, PA, November 8–13, 2011; abstract #TH-PO524Google Scholar
  31. 31.
    Fukui M, Tanaka M, Shiraishi E et al (2008) Serum uric acid is associated with microalbuminuria and subclinical atherosclerosis in men with type 2 diabetes mellitus. Metabolism 57:625–629CrossRefPubMedGoogle Scholar
  32. 32.
    Kodama S, Saito K, Yachi Y et al (2009) Association between serum uric acid and development of type 2 diabetes. Diabetes Care 32:1737–1742CrossRefPubMedPubMedCentralGoogle Scholar
  33. 33.
    Yale JF, Bakris G, Cariou B et al (2014) Efficacy and safety of canagliflozin over 52 weeks in patients with type 2 diabetes mellitus and chronic kidney disease. Diabetes Obes Metab 16(10):1016–1027CrossRefPubMedGoogle Scholar
  34. 34.
    Gembardt F, Bartaun C, Jarzebska N et al (2014) The SGLT2 inhibitor empagliflozin ameliorates early features of diabetic nephropathy in BTBR ob/ob type 2 diabetic mice with and without hypertension. Am J Physiol Renal Physiol 307(3):F317–F325CrossRefPubMedGoogle Scholar
  35. 35.
    Vallon V, Gerasimova M, Rose MA et al (2014) SGLT2 inhibitor empagliflozin reduces renal growth and albuminuria in proportion to hyperglycemia and prevents glomerular hyperfiltration in diabetic Akita mice. Am J Physiol Renal Physiol 306(2):F194–F204CrossRefPubMedGoogle Scholar
  36. 36.
    Wanner C, Lachin JM, Fitchett DH, et al. (2015) Empagliflozin and clinical outcomes in patients with type 2 diabetes and chronic kidney disease. In: American Society of Nephrology, San Diego, CA, pp abstract# HI-OR01Google Scholar

Copyright information

© Italian Society of Nephrology 2016

Authors and Affiliations

  • Donald Elliott Kohan
    • 1
  • Paola Fioretto
    • 2
  • Kristina Johnsson
    • 3
  • Shamik Parikh
    • 4
  • Agata Ptaszynska
    • 5
    Email author
  • Lisa Ying
    • 5
  1. 1.Department of Internal MedicineUniversity of Utah Health Sciences CenterSalt Lake CityUSA
  2. 2.Department of MedicineUniversity of PaduaPaduaItaly
  3. 3.Global Medical Affairs, AstraZenecaMölndalSweden
  4. 4.Global Medical Affairs, AstraZenecaWilmingtonUSA
  5. 5.Bristol-Myers Squibb, Research and DevelopmentPrincetonUSA

Personalised recommendations